Novo announced Phase III data on Wednesday that sets up semaglutide to replace its Saxenda liraglutide as an obesity treatment, and brings the company to the brink of providing a therapeutic alternative to gastric bypass...

Venclexta combo shows survival benefit in AML  Partners Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) said Venclexta venetoclax plus azacitidine significantly improved overall survival and composite complete remission rate among acute myelogenous leukemia (AML) patients...

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...

The KeyBioscience AG subsidiary of Nordic Bioscience A/S (Herlev, Denmark) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize its Dual Amylin Calcitonin Receptor Agonist (DACRA) platform to develop compounds to treat...